Andere talen Unicycive Therapeutics, Inc.

Aandelen

UNCY

US90466Y1038

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,03 ^USD	+6,19%		-3,74%	+18,70%

04/04	UNICYCIVE THERAPEUTICS, INC. : Piper Sandler verhoogt advies naar kopen	ZM
28/03	Unicycive Therapeutics, Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	10/04
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update	28/03
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress	25/03
Unicycive Therapeutics, Inc. announced that it has received $50 million in funding	20/03
Unicycive Announces $50 Million Private Placement	14/03
Unicycive Therapeutics, Inc. announced that it expects to receive $50 million in funding	14/03
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference	13/03
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia	08/03
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)	07/03
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	07/03
Thinking about buying stock in Beyondspring, LAVA Therapeutics, Unicycive Therapeutics, Guardforce AI, or Infobird?	06/03
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients	04/03
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting	14/02
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference	29/01
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones	23/01
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis	18/12
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023	29/11
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update	14/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Unicycive Therapeutics, Inc.

Aandelen

UNCY

US90466Y1038

Andere talen

Filters